Key result
Blood replacement therapy reduces stroke infarctions and neurological deficits via decreased MMP-9 in mice.
Answers are grounded in this paper and cite their sources.
Acute stroke causes complex, pathological, and systemic responses that have not been treatable by any single medication. In this study, using a murine transient middle cerebral artery occlusion stroke model, a novel therapeutic strategy is proposed, where blood replacement (BR) robustly reduces infarctions and improves neurological deficits in mice. Our analyses of immune cell subsets suggest that BR therapy substantially decreases neutrophils in blood following a stroke. Electrochemiluminescence detection demonstrates that BR therapy reduces cytokine storm in plasma and ELISA demonstrates reduced levels of matrix metalloproteinase-9 (MMP-9) in the plasma and brains at different time points post-stroke. Further, we have demonstrated that the addition of MMP-9 to the blood diminishes the protective effect of the BR therapy. Our study is the first to show that BR therapy leads to profoundly improved stroke outcomes in mice and that the improved outcomes are mediated via MMP-9. These results offer new insights into the mechanisms of stroke damage.
No takes yet. Share an insight, caveat, or question.
Ren et al. (2020) studied Acute stroke. Blood replacement (BR) therapy was evaluated on Infarctions and neurological deficits. Blood replacement therapy robustly reduced infarctions and improved neurological deficits in a mouse model of stroke, mediated via decreased MMP-9 levels.
Synapse has enriched 10 related papers. Consider them for comparative context: